Domača stranAMGN • NASDAQ
add
Amgen
276,39 $
Po zaprtju:(0,33 %)+0,90
277,29 $
Konec trgovanja: 12. sep., 19:47:15 GMT -4 · USD · NASDAQ · Izjava
Prejšnji trg. dan.
282,73 $
Dnevni razpon
276,07 $ - 282,94 $
Letni razpon
253,30 $ - 339,17 $
Tržna kapitalizacija
148,80 mrd. USD
Povprečni obseg
2,12 mio.
Razm. P/E
22,61
Dividendna donosnost
3,44 %
Primarna borza
NASDAQ
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | jun. 2025info | Sprememba L/L |
|---|---|---|
Prihodek | 9,18 mrd. | 9,43 % |
Stroški poslovanja | 3,50 mrd. | 12,82 % |
Čisti dohodek | 1,43 mrd. | 91,96 % |
Čista dobičkovnost prihodkov | 15,60 | 75,48 % |
Earnings per share | 6,02 | 21,13 % |
EBITDA | 4,34 mrd. | 5,79 % |
Efektivna davčna stopnja | 8,67 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | jun. 2025info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 8,03 mrd. | −13,69 % |
Skupna sredstva | 87,90 mrd. | −3,31 % |
Skupne obveznosti | 80,47 mrd. | −5,31 % |
Celoten lastniški kapital | 7,43 mrd. | — |
Shares outstanding | 538,36 mio. | — |
Razmerje P/B | 20,49 | — |
Donosnost sredstev | 8,47 % | — |
Donosnost kapitala | 11,81 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | jun. 2025info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 1,43 mrd. | 91,96 % |
Denar iz dejavnosti | 2,28 mrd. | −7,28 % |
Denar iz naložb | −389,00 mio. | −79,26 % |
Denar iz financiranja | −2,67 mrd. | −0,91 % |
Neto sprememba denarnih sredstev | −782,00 mio. | −92,14 % |
Prost denarni tok | 220,75 mio. | −92,64 % |
Vizitka
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
The company's major products are Prolia and XGEVA for treatment of osteoporosis and bone diseases, Enbrel for treatment of autoimmune diseases, Repatha for treatment of hyperlipidemia, Otezla for treatment of psoriasis and psoriatic arthritis, Tepezza to treat Graves' ophthalmopathy, Evenity to treat osteoporosis, Kyprolis to treat cancer, Nplate to regulate platelet production, and Aranesp to stimulate erythropoiesis.
Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection.
The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health.
The company is ranked 134th on the Fortune 500 and 202nd on the Forbes Global 2000. Wikipedia
Generalni direktor
Datum ustanovitve
8. apr. 1980
Sedež organizacije
Spletno mesto
Zaposleni
28.000
